• February 15 2017 is deadline for abstract submition.
• If an abstract is accepted for presentation, the first author must undertake to present it.
• All abstracts will initially be reviewed, graded and accepted or rejected by the Organizing Committee. The Committee reserves the right to determine whether an abstract submission is accepted as an oral presentation or a poster. The decision of the Committee is final.

• All abstracts must be submitted in English or Kazakh or Russian 
• An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
• Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
• Use generic drug names.
• Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
• Do not include references, credits or grant support.
• Do not include the names or personal information of any patient participating in the study or trial.
• The body of the abstract must not exceed 2,500 characters (not including spaces). The addition of a graphic deducts 500 characters. Graphic files should only include one image per file.

Acute Stroke,
Neurocritical Care and NICU Management,
Antiplatelet and Anticoagulant Therapies,
Endovascular Treatment of Stroke,
Management of AVMs and Aneurysms,
Management of Comorbid Conditions after Stroke,
Management of Stroke Risk Factors,
Difficult Cases in Stroke.

Evaluation Process and Acceptance Letters